A Phase II Study of Neihulizumab vs "Conventional Treatment" to Treat Steroid-refractory Acute Graft-vs-host Disease (Sr-aGvHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Trial Profile

A Phase II Study of Neihulizumab vs "Conventional Treatment" to Treat Steroid-refractory Acute Graft-vs-host Disease (Sr-aGvHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2016

At a glance

  • Drugs Neihulizumab (Primary) ; Alemtuzumab; Antithymocyte globulin; Basiliximab; Daclizumab; Denileukin diftitox; Etanercept; Infliximab; Inolimomab; Methotrexate; Mycophenolate mofetil; Pentostatin; Sirolimus
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors AbGenomics Corporation
  • Most Recent Events

    • 22 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 04 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top